Curated updates on retatrutide clinical trials, FDA regulatory actions, published research, and Eli Lilly pipeline developments. Editorially reviewed for accuracy and significance.
Current status: Retatrutide is in Phase 3 TRIUMPH trials as of September 2026. It is not FDA-approved and not commercially available. The most recent high-significance developments are active TRIUMPH enrollment and continued FDA enforcement against unapproved online vendors.
Australian TGA Tests Counterfeit Retatrutide: No Retatrutide Found, Undeclared Semaglutide at 8× Normal Level
Australia's Therapeutic Goods Administration (TGA) issued a safety alert on September 14, 2026 after testing a product sold as retatrutide following a serious adverse event report. The TGA found the product contained no retatrutide. It contained undeclared semaglutide at approximately eight times the level found in assessed semaglutide products. The consumer experienced uncontrollable vomiting and a torn esophagus requiring hospital treatment. This is an Australian TGA investigation; the U.S. FDA has not issued a parallel alert. The findings are relevant internationally because counterfeit peptide supply chains cross borders. See our pages on fake and illicit retatrutide and online peptide sellers for related safety information.
TRIUMPH-2 and TRIUMPH-3 Report Positive Topline Phase 3 Results
Eli Lilly announced positive topline Phase 3 results for TRIUMPH-2 and TRIUMPH-3 on July 23, 2026. TRIUMPH-2 participants with obesity or overweight and type 2 diabetes lost up to an average of 20.8% body weight at 80 weeks. TRIUMPH-3 participants with severe obesity and established cardiovascular disease lost up to an average of 22.6% body weight at 80 weeks. Eli Lilly now reports five positive Phase 3 retatrutide studies and states it has the clinical data package needed to support global submissions for obesity, knee osteoarthritis pain, and obstructive sleep apnea. Lilly plans to submit a regulatory application to the FDA in Q1 2027. Approval is not guaranteed.
FDA Continues Enforcement Actions Against Unapproved Peptide Vendors
The FDA has continued issuing warning letters to vendors selling unapproved peptide compounds including retatrutide analogs labeled as "research use only." The agency reiterated that RUO designation does not authorize human use and that selling such compounds for human administration violates the FD&C Act.
Eli Lilly Q2 2026 Earnings: Retatrutide Phase 3 Progress Highlighted
In its Q2 2026 earnings call, Eli Lilly highlighted progress in the TRIUMPH program and announced plans for a Q1 2027 regulatory submission to the FDA following TRIUMPH-1 topline results. The company indicated Phase 3 enrollment was proceeding on schedule.
Phase 2 Retatrutide Paper Surpasses 500 Citations in Peer-Reviewed Literature
The landmark 2023 NEJM Phase 2 retatrutide paper by Jastreboff et al. has been cited in over 500 peer-reviewed publications, reflecting the scientific community's interest in triple receptor agonism as a weight management approach. Secondary analyses examining lean mass preservation and metabolic markers continue to be published.
FDA Clarifies Compounding Status of Investigational GLP-1 Compounds
The FDA issued updated guidance clarifying that retatrutide does not currently satisfy the federal requirements that would allow it to be used as a bulk drug substance for compounding under 503A or 503B frameworks. The guidance came in response to increasing inquiries from compounding pharmacies following the high-profile compounding controversy around semaglutide and tirzepatide.
Endocrine Society Annual Meeting Features Retatrutide Subgroup Analyses
At the 2026 Endocrine Society Annual Meeting, researchers presented subgroup analyses from the Phase 2 retatrutide trials examining outcomes in participants with prediabetes, metabolic syndrome, and varying baseline BMI categories. Results suggested consistent weight loss benefit across subgroups.
Eli Lilly's Q1 2026 pipeline update listed retatrutide as a priority Phase 3 asset in the cardiometabolic portfolio. The company noted that manufacturing scale-up activities are underway in anticipation of potential commercial launch, though no approval timeline was specified.
Independent Review Confirms Phase 2 Safety Profile Consistent with GLP-1 Class
An independent pharmacovigilance review of Phase 2 retatrutide data published in a peer-reviewed journal confirmed that the adverse event profile is consistent with the GLP-1 receptor agonist drug class. Gastrointestinal events were the most common adverse effects, predominantly during dose escalation.
Eli Lilly initiated enrollment in the TRIUMPH-Outcomes trial, a long-duration cardiovascular outcomes trial evaluating retatrutide in adults with obesity and established cardiovascular disease. The trial is expected to enroll approximately 10,000 participants across multiple countries.
Lancet Publishes Phase 2 Retatrutide Data in Type 2 Diabetes
The Lancet published Phase 2 results of retatrutide in adults with type 2 diabetes, showing significant reductions in HbA1c alongside substantial weight loss. The 12 mg dose group achieved approximately 16.9% mean weight reduction at 36 weeks, with HbA1c reductions of approximately 2.0 percentage points.
The New England Journal of Medicine published the Phase 2 retatrutide obesity trial (Jastreboff et al.), reporting up to 24.2% mean weight loss at 48 weeks in the 12 mg group — the highest weight loss reported for any pharmacological agent in a published trial at that time.
As of September 2026, the most significant development is the TRIUMPH Phase 3 program. TRIUMPH-1 topline results were announced by Eli Lilly on May 21, 2026, showing 28.3% mean body weight reduction at 80 weeks (12 mg). TRIUMPH-2 (type 2 diabetes + obesity) and TRIUMPH-3 (severe obesity + cardiovascular disease) reported topline results July 23, 2026. Eli Lilly announced plans for a Q1 2027 regulatory submission to the FDA. TRIUMPH-Outcomes (cardiovascular outcomes) remains ongoing. Retatrutide is not FDA-approved and is not commercially available.
Has the FDA taken any action related to retatrutide?
The FDA has not approved retatrutide. Regulatory actions have focused on enforcement against vendors selling unapproved peptide compounds — including retatrutide analogs labeled as "research use only" — and on clarifying that retatrutide does not currently satisfy the federal requirements that would allow it to be compounded under 503A or 503B frameworks. See our FDA & Regulation page for the full regulatory timeline.
When will retatrutide Phase 3 results be published?
TRIUMPH-1 topline results were announced by Eli Lilly on May 21, 2026. TRIUMPH-2 and TRIUMPH-3 topline results were announced July 23, 2026. Peer-reviewed publication of the full datasets is pending. TRIUMPH-Outcomes (cardiovascular outcomes) remains ongoing as of September 2026. The TRIUMPH-Outcomes trial is a long-duration outcomes trial expected to run approximately 5 years. Results will be submitted to peer-reviewed journals and presented at major medical conferences.
What did the NEJM Phase 2 paper show?
The landmark 2023 NEJM paper (Jastreboff et al.) reported up to 24.2% mean weight loss at 48 weeks in the 12 mg retatrutide group, compared to 2.1% on placebo. This was the highest weight loss reported for any pharmacological agent in a published trial at the time of publication. The paper has since been cited in over 500 peer-reviewed publications.
Is retatrutide safe based on current evidence?
Phase 2 data and an independent pharmacovigilance review confirm that retatrutide's adverse event profile is consistent with the GLP-1 receptor agonist drug class. Gastrointestinal events (nausea, vomiting, diarrhea) are the most common adverse effects, predominantly during dose escalation. Phase 3 safety data are pending. See our Safety Center for a full breakdown of known adverse events.
Can I buy retatrutide based on news reports about its results?
No. Positive clinical trial results do not make a drug legally available. Retatrutide has no FDA-approved NDA. Vendors selling "retatrutide" online are selling unapproved compounds that may be mislabeled, contaminated, or counterfeit. The only legal way to access retatrutide is through an authorized clinical trial registered on ClinicalTrials.gov.
